Low Colorectal Tumor Removal by E-Cadherin Destruction-Enabled Tumor Cell Dissociation

• DOI: 10.1021/acs.nanolett.1c04797
• Publication Date: 2022-03-25T23:47:25Z
• Authors: Man Li; Qunqun Bao; Jing Guo; Ruting Xie; Chao Shen; Qing Wei; Ping Hu; Huanlong Qin; Jianlin Shi
• Keywords: 0301 basic medicine; 0303 health sciences; 03 medical and health sciences; Cell Line, Tumor; Tumor Microenvironment; Humans; Cadherins; Colorectal Neoplasms; Edetic Acid; 3. Good health

Treatments for low colorectal cancer (CRC) remain a great challenge due to the heavy physical and psychological burdens of colostomy, strong drug toxicity in chemotherapy, and myelosuppression-/chemoradiation-related gastrointestinal symptoms. In this study, a highly biosafe and effective tumor cell dissociation-based low CRC treatment modality has been verified on both PDOs in vitro and colorectal tumor models in vivo. Notably, controllable EDTA release at the tumor sites was achieved by the LDH degradation in response to a slightly acidic microenvironment of low CRC tumors. Resultantly, the intratumoral E-cadherin for intercellular junctions of low CRC tumors was effectively destroyed via Ca2+ depletion by released EDTA from the interlayers, initiating remarkable tumor cell dissociation and resultant tumor disaggregation/removal via defecation. Dissociated tumor cells were prevailingly enveloped by LDH/EDTA, which prevented them from readhering to adjacent tissues, providing an unprecedented, efficient and safe therapeutic modality for low CRC, which will benefit patients suffering low CRC.